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Abstract: The adult liver contains a population of facultative progenitor cells (known variously as Oval Cells, 
Hepatic Progenitor Cells, HPCs, or proliferating Biliary Epithelial Cells, BECs) which, following injury, proliferate 
and differentiate into hepatocytes, thereby restoring liver function. Although previous studies have shown that 
Notch signalling is essential for bile duct formation from these cells, it has not been determined whether Notch 
signalling is required for BECs to replenish hepatocytes following injury in the mammalian liver. This limitation 
is largely due to the mammalian models used to study hepatic repair from BECs, which rely on chronic damage 
and continual proliferation of BECs. In this study, we use a strict model of hepatic repair where large-scale 
hepatocyte injury and regeneration is initiated through the acute loss of Mdm2 in hepatocytes. This results in a 
rapid, coordinated proliferation of BECs allowing us to dissect the role of Notch signalling in this process. We 
find that transient, early activation of Notch signalling and entrance into cell cycle precedes the phenotypic 
expansion of BECs. Notch1 and Notch3 mediate this process and accordingly Notch inhibition results in the 
reduction of BEC proliferation. This decrease in BEC number results in a failure of BECs to differentiate into 
hepatocytes, indicating that Notch-dependent expansion of BECs is essential for hepatocyte regeneration. 
Finally, we found that Notch signalling regulates insulin-like growth factor-1 receptor (IGF1R) levels and show 
that activation or inhibition of IGFR1 signalling regulates BEC number. Critically, increasing BEC number (by 
activating IGFR signalling) suppresses the differentiation of BECs into hepatocytes, suggesting that BEC 
expansion has different signalling mechanisms to hepatocyte differentiation.   
Introduction: 
Following injury, the adult liver is able to regenerate from a population of facultative Biliary Epithelial Cells (BECs) 
that proliferate and differentiate into hepatocytes in response to injury, thereby reconstituting damaged 
epithelial cells and restoring normal liver function(1, 2). Throughout regeneration, a cellular and acellular 
microenvironment surrounds BECs (also known as Hepatic Progenitor Cells, HPCs or Oval Cells) (3) and provides 
a number of developmental signals(4–7). These signals are responsible for maintaining a balance between BEC 
proliferation and differentiation, thereby ensuring that regeneration is sufficient, collectively, in human disease, 
BECs and this microenvironment are termed the ductular reaction (8). BECs are able to differentiate into two 
epithelial lineages, cholangiocytes that make up the bile duct, a tubular network that drains bile form the liver 
into the bowel and hepatocytes, which comprise the metabolically active parenchyma of the liver. Following bile 
duct injury, we and others have shown that Notch signalling is necessary for BECs to reconstitute the bile duct 
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and as such Notch signaling is considered a master-regulator of the ductular lineage(9, 10). Whether Notch 
signalling is required for BECs to regenerate hepatocytes following hepatic injury in the mammalian liver is not 
clear, although recent data from a number of studies in the Zebrafish, suggests that Notch signalling maintains 
BECs in a naïve state and that BECs can differentiate when the suppressive effects of Notch signalling are 
removed (11–13). These data from the fish suggest that contrary to evidence in mouse, Notch signaling does 
function in the replenishment of hepatocytes after injury. A limitation of previous murine studies investigating 
the signals that govern the proliferation and differentiation of BECs into hepatocytes, is that the majority of 
murine models rely on establishing chronic hepatic injury. This results in a continuous activation, proliferation 
and differentiation of BECs. Therefore in these models, BECs are at various stages of their lifecycle, making it 
difficult to resolve the signals that govern the various states of proliferation and differentiation(14–16).  
To overcome this, we used a model where largescale, liver-wide injury is induced by the acute genetic loss of 
Mdm2 in hepatocytes(2, 17). In this model, hepatocytes become senescent(18) and as a result BECs undergo 
coordinated activation and proliferation ultimately differentiating to reconstitute hepatocytes. Using this 
approach, we have been able to resolve in a temporal way the role of Notch signalling during hepatocyte 
regeneration from BECs and we describe how Notch signalling is activated prior to the overt expansion of BECs 
in the liver. In this model of acute hepatocyte Mdm2-loss we have found that Notch signalling promotes BEC 
proliferation by modulating the levels of IGF1R, thereby sensitising BECs to IGF1. Through modulating this Notch-
IGF1R pathway in vivo, using a combination of animal models (both of acute hepatocyte Mdm2-loss as well as 
classical dietary-induced injury models, MCD and CDE, where hepatocytes have been shown to arise from the 
differentiation of BECs or HPCs(2, 19)) we have found that the numbers of BECs can be altered. Importantly, 
suppression of BEC proliferation results in a failure of BECs to differentiate into hepatocytes indicating that in 
hepatic regeneration a sufficient number of BECs must be generated before differentiation can occur. To our 
surprise, we also found that increasing BEC number through IGF1 signalling inhibits differentiation, leading us to 
conclude that there is a fine balance between BEC generation and their differentiation into hepatocytes, that 






Notch signalling is activated early in BECs following hepatic injury. The Notch signalling pathway is essential for 
the formation of bile ducts from embryonic hepatoblasts(20, 21) and is reactivated in adult bile duct 
regeneration where it directs BECs into a cholangiocyte lineage(9, 22, 23), therefore we sought to address 
whether Notch also regulates hepatocyte regeneration from BECs. We have previously described a mouse model 
of hepatic regeneration where large numbers of hepatocytes can be generated from BECs (2, 17). Known as the 
Ah-Cre::Mdm2fl/fl mouse, this model relies on the specific expression of Cre recombinase in hepatocytes 
following administration of β-napthoflavone, which activates the Cyp1a1 promotor to drive Cre expression. In 
these mice, both alleles of Mdm2 are also flanked by LoxP sites; as a result, following Cre activity Mdm2 is excised 
resulting in the stabilisation of TRP53 and upregulation of p21 in hepatocytes. In this model, large scale 
hepatocyte senescence (driven by p21 upregulation), results in liver injury (Supplementary Figure 1A), 
hepatocyte apoptosis (Supplementary Figure 1B) and BEC proliferation and differentiation in order to 
reconstitute the liver parenchyma(2, 17). As liver regeneration is initiated at a single time point (when β-
napthoflavone is administered) it is possible to track the temporal dynamics of BECs as they proliferate prior to 
their differentiation into hepatocytes.  
Following Mdm2-loss in Ah-Cre::Mdm2fl/fl mice, the number of panCK positive BECs begins to increase 
throughout the liver within 5-7 days following induction and by 14 days following induction, there are 
significantly higher numbers of panCK-positive BECs that invade into the parenchyma compared to mice that 
still have intact Mdm2 (Figure 1A). These cells are also positive for the BEC marker, SOX9 (Supplementary Figure 
1C). Given the rapid increase in BECs following hepatic injury, we hypothesised that biliary epithelial cells would 
continuously proliferate to generate large numbers of daughter cells in order to replenish lost hepatocytes; 
therefore we stained Mdm2-deleted livers for KI67, a marker of proliferation.   
Contrary to what we expected, the proportion of proliferating BECs is high early-on (between days 3-5) following 
initiation of injury, when we begin to see the emergence of BECs, however this is not maintained throughout 
regeneration and after 5 days, the proportion of BECs in the cell cycle decreases (Figure 1B). As Notch signaling 
is mitogenic in other progenitor cell systems(24, 25) and is required for bile duct regeneration (9, 10), we 
evaluated whether components of the Notch signalling pathway are expressed during hepatocyte repair. 
Following initiation of injury, there is a rapid increase in the mRNA expression of Notch receptors, Notch1 and 
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Notch3 (Figure 1C) between days 3-5 of regeneration but not Notch2 (Supplementary Figure 1D) and Notch 
ligands, Jagged1 and Jagged2 (Figure 1D). Dll1 was the only other Notch ligand detectable and this did not 
change throughout the time course (Supplementary Figure 1D).  To verify that the Notch signalling pathway is 
activated in proliferating BECs, used a transgenic mouse line, CBF::H2BVenus that reports active Notch signalling 
with single cell resolution(26) and crossed this into our AhCre::Mdm2fl/fl line, such that we could identify cells 
that have active Notch signaling during hepatocyte regeneration (known as AhCre::Mdm2fl/fl::CBFH2BVenus). We 
found that proliferating BECs were strongly positive for the Venus (eYFP) in the early phase (day 5) following 
hepatocyte Mdm2 recombination (Figure 1E), suggesting that in line with the expression of Notch receptors, this 
signaling pathway is also active. The transcriptional expression of Notch pathway components is reduced at later 
time points, having peaked at 3-5 days following hepatocyte Mdm2-loss. To validate independently that the 
Notch pathway is activated in BECs, we stained liver tissue from mice with hepatocyte Mdm2-deletion for Notch 
pathway components and found that NOTCH1 and NOTCH3 proteins are expressed by BECs at day 3 and day 5, 
respectively. Furthermore, NOTCH1 intracellular domain localises to the nucleus of BECs reiterating that the 
Notch-1 receptor is cleaved and the pathway is activated (Figure 1F, single stains available in Supplementary 
Figure 5). Previous work in ductular regeneration has shown that the Notch ligand, JAGGED1 is expressed by 
myofibroblasts surrounding proliferating ducts (9), however during hepatocyte regeneration from BECs, we 
could find little evidence indicating Notch ligands are expressed by fibroblasts or macrophages, rather JAGGED1 
is expressed by the BECs themselves (Figure 1G).  
Inhibition of Notch signalling impairs BEC proliferation and hepatocyte differentiation. Whilst the expression of 
Notch pathway components correlates with an increased number of BECs entering the cell cycle, it is not clear 
whether Notch signalling drives proliferation of BECs per se. To determine whether this is the case, we induced 
Mdm2-loss in hepatocytes to induce BEC proliferation and gave a pharmacological inhibitor of Notch signalling, 
DAPT, that prevents the activity of γ-secretase, thereby preventing Notch receptor cleavage (from hereon-in 
known as Notch-i). As our model relies on a single genetic insult to initiate injury and hepatocyte regeneration, 
we were able to inhibit Notch signalling either early during regeneration or later in this process (Figure 2A). 
When we administered Notch-i early during regeneration (between days 2 and 4 following injury), the point 
where the Notch signalling is highly activated, the number of BECs that were proliferative and the total number 
of panCK positive BECs was significantly reduced (Figure 2B). When Notch-i was administered late, at a point 
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where Notch1 and Notch3 mRNA levels are lower (at 7-10 days following injury), the number of proliferative 
BECs remained the same, demonstrating that Notch signalling only drives BEC proliferation in the early phases 
of hepatocyte repair (Figure 2B and 2C). Given that inhibition of γ-secretase can influence a number of cleaved 
cell surface proteins along with Notch-receptors, we sought to verify that NOTCH1 and NOTCH3 specifically 
regulate BEC proliferation. Following hepatocyte Mdm2-loss and the activation of BECs, we inhibited NOTCH1 
and NOTCH2 receptors using receptor specific inhibitory antibodies (administered 1 day following Mdm2-loss) 
or NOTCH3 through genetic deletion using a Notch3-/- mutant mouse line. Inhibition of NOTCH1 and deletion of 
NOTCH3 significantly reduced the number of proliferative BECs and the total number of panCK-positive BECs 
following injury in vivo (Figure 2D) and are associated with a significant reduction in BEC proliferation and mRNA 
expression of Notch pathway target genes in vitro (Supplementary Figure 2A -2F). Inhibition of the Notch 
signalling pathway (either with DAPT, blocking antibodies or through receptor deletion) and reduction in BEC 
numbers did not appear to make liver injury worse (as determined by ALT levels, Supplementary Figure 2G-J). 
However, in the context of NOTCH1 inhibition or genetic NOTCH3 deletion (where BEC proliferation is reduced) 
we found that the levels of serum Bilirubin are significantly decreased, suggesting that the formation of a 
ductular reaction, in these models at least, contributes to cholestasis (Supplementary Figure 2K and 2L). 
Recent work has suggested that BECs differentiate into hepatocytes and that these differentiated cells then 
undergo proliferation to reconstitute the parenchyma(27). To determine whether inhibition of Notch signalling 
and reduced BEC numbers affected hepatocyte differentiation, we utilized an Osteopontin driven CreERT2 (OPN-
iCREERT2::R26ReYFP) to irreversibly label BECs and their progeny with eYFP such that we can monitor the 
differentiation of BECs into hepatocytes (19). In the healthy adult mouse liver, OPN- iCREERT2 only labels BECs. In 
injury, however, hepatocytes have also been shown to upregulate OPN, therefore to ensure we did not capture 
any other cells and that we only labelled BECs we dosed animals with tamoxifen and then left them for a 2-week 
“wash-out” prior to initiating injury(28).  Hepatocyte injury was induced by feeding OPN-iCREERT2::R26ReYFP mice 
a Choline Deficient, Ethionine Supplemented diet, CDE (Figure 2E), and the proportion of hepatocytes labelled 
with eYFP (Figure 2F) is significantly higher than in uninjured livers (Figure 2G), as previously described(19). 
Following Notch-i in these OPN-iCREERT2::R26ReYFP, CDE-fed mice, however, the number of proliferative eYFP+ 
BECs is reduced (Supplementary Figure 3A, left panel) as too are the number of lineage traced hepatocytes 
(Figure 2F and 2G).  We also confirmed that in a second dietary model of hepatocyte injury, the Methionine-
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Choline Deficient (2), MCD model that Notch-i consistently reduces the number of proliferating BECs 
(Supplementary Figure 3A, right panel) demonstrating that BECs proliferation driven by Notch signaling is not 
restricted to the CDE model. Collectively, our data indicate that Notch-dependent BEC proliferation is essential 
for normal hepatocyte reconstitution from a BEC origin. 
Notch signalling regulates the expresson of IGF1R by BECs. Notch signalling is involved in the expansion of 
progenitor cell pools in a range of developmental and adult tissues(29–31). It is widely accepted, however, that 
Notch does this by supressing differentiation and maintaining progneitor cells in a state that is receptive to 
mitogenic signals(32, 33). In Alagille syndrome, loss of Notch signalling due to mutations in Jagged1 results in 
the dysregulation of IGF1 signalling(34) therefore we sought to determine whether Notch signalling can regulate 
IGF1 signalling in adult BECs and define whether IGF1 induces BECs to proliferate.  
Following deletion of Mdm2 in hepatocytes and initiation of hepatic regeneration from BECs, both IGF1 and its 
activated receptor,  pIGF1RY1161 are expressed by BECs in vivo (Figure 3A) and throughout the timecourse 
following Mdm2-inactivation, the mRNA expression of Igf1r, maps closely with the expression of the Notch 
pathway target gene, HeyL (Supplementary Figure 3B). In vitro, the BEC cell line, BMOL produce their own IGF1, 
which they secrete into the media (Figure 3B).  Following treatment with Notch-i in vitro, BMOLs do not reduce 
their expression of Igf1 at the mRNA level (Supplementary Figure 3C), rather the levels of Igf1r transcript (Figure 
3C) and IGF1R protein (Figure 3D and Supplementary Figure 3D) are significantly decreased, suggesting that 
Notch inhibition can regulate signalling through the IGF1 pathway through modulation of the IGF1 receptor 
levels in vitro. Finally, consistent with this, we measued the transcript levels of both Igf1 and Igf1r in mice that 
had received Notch-i for three days during early hepatocyte regeneration (following Mdm2-deletion in the Ah-
Cre::Mdm2fl/fl line) when Notch1 and Notch3 are most highly expressed (Figure 2A) and found that expression 
of Igf1r mRNA, but not that of Igf1 was significantly reduced (Figure 3E). Furthermore, in these Ah-Cre::Mdm2fl/fl 
mice undergoing hepatcoyte regeneration, when treated with Notch-I the expression of pIGF1RY1161 is reduced, 
whereas in vehicle treated animals, pIGF1RY1161 is expressed and localises to the plasma membrane of BECs 
(Figure 3F).  
Signalling through the IGF1-receptor directly regulates BEC proliferation: Having identified that Notch signalling 
can regulate the expression of IGF1R in BECs and given that IGF1-IGF1R signalling is a potent mitogen for other 
cell types, we sought to address whether signalling through IGF1R promotes the proliferation of BECs. In vitro, 
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BECs treated with the IGF1R inhibitor AG1024, reduced their proliferation in a dose dependant manner 
(Supplementary Figure 4A), indicating that IGF1-IGF1R signalling is mitogenic in BECs. In vivo, IGF1R is expressed 
by a number of different cell types(35), therefore, to better undertand the role of IGF1 signalling in hepatic 
regeneration, we conditionally deleted Igf1r (using Igf1rflox mice) in BECs using the OPN-CreERT2 transgenic 
mouse line, whilst concurrently labelling them with eYFP (known as OPN-CreERT2::IGF1fl/fl::R26ReYFP mice) (Figure 
3G) and inducing liver injury by feeding mice a hepatotoxic CDE diet. Following CDE-induced hepatic injury, OPN-
CreERT2::IGF1fl/fl::R26ReYFP mice, which lack Igf1r in their BECs failed to amount a proliferative BEC response as 
determined through a reduced number of eYFP positive BECs, similarly the number of eYFP-positive BECs 
entering cell cycle was also significantly reduced (Figure 3H).  Given that IGF1-IGF1R signalling is a potent 
activator of the AKT/mTOR signalling pathway, we verified that phospho-mTOR was expressed by proliferating 
BECs in Ah-Cre::Mdm2fl/fl mice folloing Mdm2-deletion (Supplementary Figure 4B) and then inhibited this by 
treating Ah-Cre::Mdm2fl/fl mice undergoing BEC-mediated hepatcoyte regeneration with Rapamycin. In 
Rapamycin treated mice we found fewer proliferating BECs in vivo compared to vehicle treated animals 
(Supplementary Figure 4C and 4D), suggesting that mTOR can promote BEC proliferation.  
Therapeutic modulation of BEC number with IGF1 does not result in increased hepatocyte regeneration: One of 
the ultimate aims of regenerative medicine is to identify small molecules that can alter the regenerative 
response and improve tissue repair. A core tenant of many therapies is that increasing the pool of endogenous 
stem or progenitor cells will ultimately improve the regenerative output of the tissue. Whether this is actually 
true in BEC mediated liver regeneration, however, has not been determined.  
Our data indicates that therapeutic modulation of Notch-IGF1 signalling could affect BEC number and ultimately 
alter how many hepatocytes are replenished following injury. As BEC number undergoes rapid expansion from 
day 5 following hepatocyte Mdm2-loss, and that this is the point at which Igf1r mRNA is most highly expressed, 
we treated Ah-Cre::Mdm2fl/fl mice with either AG1024 (known as IGF1R-i) to reduce signalling through IGF1R or 
recombinant IGF1 (rIGF1), to stimulate IGF1R activation 6-9 days following hepatocyte Mdm2-loss. Following 
treatment with IGF1R-i, the number of proliferating BECs is reduced, as is the total number of BECs throughout 
the liver, indicating that BECs respond to IGF1 signalling levels during hepatocyte regeneration (Figure 4A and 
4B). Conversely, treatment with rIGF1, significantly increases the number of BECs that enter cell cycle compared 
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to animals that received control treatment and the overall number of BECs within the liver is increased (though 
this does not reach statistical significance) (Figure 4C and 4D).  
Having determined that modulation of IGF1R through either therapeutic inhibition or activation can directly 
affect the number of BECs that are proliferative in the Ah-Cre::Mdm2fl/fl model following hepatic injury, we 
sought to determine whether increasing the pool of BECs in the liver would increase the number of BEC derived 
hepatocytes. To do this, we utilised a previously published model of regeneration where hepatocyte senescence 
is induced in the liver of Krt19CreERT::R26tdTomato transgenic mice by expressing p21 in hepatocytes (using an 
AAV8:TBG-p21, an adeno associated virus that is highly specific for hepatocytes) and injuring the liver using the 
hepatotoxic MCD diet (2). Recent work has shown that, in the context of injury, the Krt19CreERT mouse does not 
have ectopic activation of the Cre transgene in hepatocytes (28) and so represents the most robust tool for 
genetically labelling and lineage tracing BECs in order to assess BEC to hepatocyte differentiation, particularly 
when the number of hepatocytes arising from BECs could be limited.  As previous studies have shown that 
following the withdrawal of MCD-induced injury, hepatocytes can be lineage traced from K19-positive BECs (by 
staining for tdTomato) in this mouse line, we administered rIGF1 or vehicle alone to this model to determine 
whether stimulating IGF1R results in the formation of more lineage traced hepatocytes (Figure 4E). Following 
rIGF1 treatment, the number of proliferating BECs and total number of BECs within the livers of rIGF1 treated 
mice was increased at the end of this study (Figure 4F), reiterating that supplementing rIGF1 is able to increase 
BEC number in a range of murine models of hepatocyte regeneration. Finally, we stained and quantified tissue 
for lineage traced (tdTomato-positive), HNF4α-positive hepatocytes. Interestingly, we found that there was a 
significant reduction in tdTomato positive hepatocytes lineage traced from BECs (Figure 4G and 4H), indicating 
that increasing BEC number alone is insufficient to increase BEC to hepatocyte differentiation (summarised in 
Figure 4I). 
Together, our data show that the Notch signalling pathway is necessary for the proliferation of BECs destined to 
become hepatocytes and that Notch does this by promoting BECs to become sensitive to signalling through 




The role of Notch signalling in bile duct development is well described(20, 34, 36) and recent work has shown 
that these developmental signalling pathways are reactivated in the adult when bile ducts are injured(9, 10). 
However, early data from us and others indicated that there was not a role for Notch signalling in hepatic 
regeneration; Biliary Epithelial Cells that were destined for hepatocyte differentiation had Notch pathway 
components transcriptionally down regulated and Notch’s function was suppressed in BECs through the 
expression of the E3-ligase, Numb(9, 12). Previous mammalian models of hepatic regeneration promoted BEC 
proliferation and differentiation(16). In these models, progenitor cells were continually generated; undergoing 
proliferation and differentiation at different rates, therefore identifying pathways that regulated BEC 
proliferation and differentiation in the mammalian liver has been difficult, though data form zebrafish has 
suggested that Notch signaling is required for BEC to hepatocyte differentiation(12, 13). Recent advances in 
mammalian models of liver regeneration, however, have provided new tools to answer fundamental questions 
about BEC biology(2). These types of models, where a single, timed insult results in the proliferation and 
differentiation of BECs into hepatocytes have been discussed elsewhere(37, 38), however they allow, for the 
first time, temporal resolution of the signalling pathways involved in hepatocyte regeneration from a progenitor 
cell. Single cell RNA (scRNA) sequencing from regenerating adult livers has found that the Yap signalling pathway 
is critically important for BEC proliferation. These studies have indicated that Yap signalling, through the 
upregulation of Notch, could promote the proliferation of BECs. Whether this is a direct action of Notch acting 
as a mitogen or whether Notch signalling allows BECs to become sensitised to other mitogenic signals was not 
investigated(6, 7).  
We hypothesised that Notch signalling sits at the centre of a signalling network (potentially regulated by Yap 
signalling) which then maintains BECs in a state permissive to proliferation. Here, we show that two Notch 
receptors (Notch1 and Notch3) are increased in a temporally restricted manner. Notch2 (which has an essential 
role in bile duct development during embryogenesis) does not change overtime and Notch4 was undetectable 
(Supplementary Figure 1D). In our model, activation of Notch1 or Notch3 signalling promotes the proliferation 
of BECs. However, specific inhibition or genetic deletion of these single receptors is sufficient to reduce the 
number of BECs in cell cycle, suggesting that signalling through Notch1 and Notch3 is not redundant and 
indicating that Notch1 and Notch3 might play different roles in the activation and subsequent proliferation of 
BECs. Of note, we found that in our model of large scale hepatocyte regeneration (using the AhCre::Mdm2fl/fl 
11 
 
line) that the proliferation of BECs precedes hepatocyte apoptosis. The proliferation of BECs has previously been 
associated with the formation of an inflammatory microenvironment(39–41) and indeed signalling from immune 
cells to BECs has been shown to initiate the formation of the ductular reaction(42, 43). At a tissue level, this 
temporal separation of BEC proliferation and differentiation, and the apoptosis of hepatocytes makes sense as 
the number of BECs-derived hepatocytes needs to be sufficicent to maintain liver function prior to the clearance 
of injured hepatocytes. However, what maintains this balance in regeneration is poorly defined.  
What is clear from our studies is that Notch signalling increases the sensitivity of BECs to stimulation with IGF1, 
through positivity regulating IGF1R signalling in BECs. Inhibiting Notch signalling or inhibiting signalling through 
the IGF1R axis, is sufficient to reduce the number of BECs cells in cycle. This has interesting implications for both 
liver cancer, which appears to rely on the activation of developmental signalling pathways, including Notch(44, 
45), and also in regenerative medicine, where relatively few therapeutically tractable signalling pathways have 
been identified that can increase the number of progenitor cells within a regenerating system. In this study, we 
identify IGF1 as one such factor, which increases the number of proliferating BECs and has the potential to 
improve progenitor-mediated regeneration. In our work in animal models of hepatocyte regeneration from 
BECs, however, we found that expansion of BECs was insufficient to regenerate more hepatocytes, instead, we 
found that increasing the number of BECs suppressed hepatocyte differentiation compared to control animals. 
The relationship between proliferation and differentiation in stem/progenitor systems is complex and requires 
the integration of a number of pro-proliferative factors (such as cyclin dependent kinases) with pro-lineage 
regulators (such as transcription factors). How these two states are reconciled in hepatic regeneration is not 
known, however recent work investigating the epigenetic landscape in BEC mediated liver regeneration could 
start to unpick the relationship between these two fundamental cellular states(46, 47). We cannot discount 
another outcome of course, that IGF1R signalling can directly suppress BEC-to-Hepatocyte differentiation, and 
further work is needed to understand this, particularly given the biphasic role of Notch in BEC differentiation in 
zebrafish models of hepatocyte regeneration(11, 12). 
This work highlights the importance of Notch-IGF1 signalling in hepatocyte regeneration and rather than being 
a strict signal, positioning BECs into the cholangiocyte lineage, Notch acts as a common signal to expand 
progenitor cells prior to their differentiation. Furthermore, these data suggest that increasing the number of 
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BECs in patients with hepatic injury maybe insufficient to promote regeneration, additional therapies that drive 
expansion and differentiation would be required.  
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Materials and Methods: 
Animal studies: AhCre MDM2 strains: AhCre::MDM2fl/fl were crossed with Notch3d1 (Notch3-/-) to give 
AhCre::MDM2fl/fl::Notch3+/+, AhCre::MDM2fl/fl::Notch3-/- strains. AhCre::MDM2fl/fl were also crossed with CBF-
H2BVenus  transgenic Notch reporter mice to give AhCre::Mdm2fl/fl::CBFH2BVenus. OPN-iCreERT2::R26RYFP mice were 
crossed with Notch3-/- as above to give OPN-iCreERT2::R26RYFP::Notch3+/+ and OPN- CreERT2::R26RYFP::Notch3-/-, 
and Igf1rfl/fl (Jackson Laboratories stock number 012252) to give OPN-iCreERT2::R26RYFP::Igf1rfl/fl and OPN-
iCreERT2::R26RYFP::Igf1rwt/wt.  
 
All AhCre MDM2fl/fl strains received 20mg/kg beta-naphthoflavone (BNF) (Sigma-Aldrich) in corn oil intra-
peritoneal (i.p.) for Cre induction. For Notch inhibition experiments mice received 50mg/kg/dose DAPT (N-[N-
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) (Sigma-Aldrich) or equivalent volume of vehicle 
daily for 3 days by i.p. injection. Notch1 (clone: aN1_E7 or aN1_E10) or Notch2 (clone: aN2_B6 or aN2_B9) 
blocking antibody or control antibody was administered by single dose of 10mg/kg by i.p. injection 24 hours 
after Cre-induction. AhCre::MDM2fl/fl::Notch3+/+ and AhCre::MDM2fl/fl::Notch3-/- mice received only BNF 
induction. Mice in experiments receiving inhibitors or agonists of the IGF1-mTOR axis received daily i.p. injection 
of: AG1024 (Santa Cruz Biotechnology) 30ug/dose or vehicle, rapamycin (Sigma-Aldrich) 10mg/kg/dose or 
vehicle or recombinant murine IGF1 (rIGF1) (Sigma-Aldrich) 0.5mg/dose or vehicle. OPN-iCreERT2::R26RYFP mice 
received the CDE-stop protocol (choline-deficient ethionine-supplemented diet, MP Biomedicals) as previously 
described, commencing Cre-induction with tamoxifen at 21 days and injury diet at least 14 days after final 
tamoxifen dose when the mice reached 20g. During the 2 week ‘STOP’ period DAPT (25mg/kg) or equivalent 
volume of vehicle was administered three times per week by i.p. injection. OPN-iCreERT2::R26RYFP strains OPN-
iCreERT2::R26RYFP::Notch3+/+, OPN-iCreERT2::R26RYFP::Notch3-/-, OPN-iCreERT2::R26RYFP::Igf1rfl/fl and OPN-
iCreERT2::R26RYFP::Igf1rwt/wt having been generated through crosses with mice on a C57/Bl6 background.  
 
To determine whether IGF1 affects the formation of lineage traced hepatocytes (Figure 4), a mixture of males 
and female 8-12 week old Keratin19-CreERT::R26RtdTomato mice were used.  
The Keratin19-CreERT::R26RtdTomato mice were induced by 3 individual i.p. injections of Tamoxifen (20mg/ml, 
Sigma) at the dose of 4mg. Mice received two weeks of normal diet after the last Tamoxifen injection. 5 x 1011 
14 
 
viral AAV8.TBG.p21 (Addgene) particles were reconstituted in 100µL and injected intravenously through tail vein 
injection with Ultra-Fine Insulin Syringes (BD). Mice receive one more week of normal diet before starting 
Methionine and Choline Deficient (MCD) diet (MP Biomedicals) for 14 days followed by four days of normal diet. 
Then the mice received two intraperitoneal daily doses of recombinant murine-IGF1 (Peprotech, prepared at 
0.05 mg per dose in 100 ul of sterile saline) or saline control during four consecutive days followed by four 
additional days of recovery on normal diet. In our lineage tracing study, one animal of the saline group did not 
have a tdTomato expression and was therefore excluded from the analysis of the tdTomato+ hepatocytes. 
All animal experiments were conducted in accordance to the UK Home Office PPL awarded to Prof Stuart Forbes. 
All mice were genotyped by Transnetyx (Memphis, TN, USA) and were maintained in 12h light/dark cycles on a 
predominantly C67Bl6/J genetic background. 
 
Cell culture: The BEC cell line BMOL was maintained in WilliamsE medium containing 2% foetal calf serum (FCS) 
(Life Technologies). Cells were tested for the presence of mycoplasma in-house at the beginning of the study 
and were found to be negative. For in vitro cell viability assays, cells were plated at 2x105/cm2 density and 
treated for 48 hours with DAPT or AG1024 or the relevant vehicle at the concentrations detailed in the figures. 
Anti-Notch antibodies or control were used at 10μg/ml. MTT assay was conducted using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (5mg/ml) (Sigma-Aldrich) diluted in PBS (Sigma-Aldrich). Cells were 
treated for 12 hours, and MTT crystals were dissolved in DMSO and read at 570/690nm using a FluoStar Omega 
(BMG Labtech). EdU incorporation assay (ThermoFisher Scientific) was conducted as described in the 
manufacturer’s instructions after 24-hour treatment of cells with DAPT (10μM), or volume-matched DMSO. 
 
Immunohistochemistry: At sacrifice, livers were perfused with 5mls sterile PBS into the IVC before fixation 
overnight in 10% buffered formaldehyde. After paraffin embedding, tissue sections were cut at 4 μm. After de-
waxing sections were subject to heat-mediated antigen retrieval followed by blocks to peroxide (Vector), 
avidin/biotin (Life technologies) where appropriate prior to protein block (Vector). Sections were incubated 
overnight with primary antibodies at 4°C. After washing, sections were stained with species-appropriate 
secondary antibodies conjugated to Alexa 488, Alexa 555 (Life technologies), or Biotin (Vector). For colorimetric 
stains, sections were incubated with ABC reagent (Vector) and developed using DAB (Vector) before 
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counterstaining with Harris Haematoxylin and Scott’s tap water.  For a complete list of primary antibodies, see 
Supplementary Table1. 
 
Microscopy and cell counting: Images were obtained on a Nikon Eclipse E600 microscope. Cell counts were 
performed manually using Fiji ImageJ (EMBL) on blinded slides and more than 20 consecutive non-overlapping 
fields at x200 (colorimetric) or x400 (immunofluorescent) magnification. Interlobular bile ducts were excluded 
from quantification. Picrosirius red quantification was performed on 30 consecutive non-overlapping x200 fields 
by pixel analysis using Adobe Photoshop CS6. 
 
For analysis of PCNA positivity in RFP or YFP-expressing cells after performing immunofluorescent staining for 
the fluorescent reporter, PCNA and DAPI, slides were scanned using the Operetta high-content analysis system 
(PerkinElmer). A minimum of 30 10X long working distance objective fields (0.4cm2) liver tissue was analyzed 
using the Columbus image data storage and analysis system. Briefly, a sliding parabola was applied to the DAPI 
channel to remove variation in background level across and between samples. All nuclei were identified using 
method M standard settings and from this population, cells positive for the reporter were identified based on a 
common threshold. From this second population those with nuclear PCNA staining were again identified using 
a common threshold. Results are reported as % RFP or YFP positive cells also PCNA positive. Fields containing 
artefacts that affected image analysis were excluded manually.  
 
Quantification of the percentage of biliary-derived hepatocytes (Figure 4) was done in a semi-automated 
manner. 35 non-overlapping images (x20 magnification) were acquired per mouse using Operetta High Content 
Imaging System (Perkin Elmer). Total cell count (DAPI-positive nuclei) and total hepatocyte count (HNF4α-
positive nuclei) were quantified in an automated manner using a segmentation strategy and Columbus image 
analysis software (Perkin Elmer). Biliary-derived hepatocytes were quantified manually, identified by the co-
localisation of DAPI and HNF4α in the nucleus and tdTomato-positive cytoplasm. 
 
Real-time PCR and gene expression analysis: Cells and tissues were lysed into Tri-Reagent (Ambion) and 
homogenized. Lysates were mixed with 1:5 chloroform/TriReagent and the aqueous phase containing RNA was 
collected.  Cells were lysed directly into RLT lysis buffer (Qiagen). RNA was precipitated with isopropanol. The 
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precipitate was applied to an RNeasy Mini column (Qiagen) according to the manufacturer’s protocol. Isolated 
RNA was quantified using a NanoDrop 1000, and 1μg was reverse transcribed using the Quantitect RT kit 
(Qiagen) as per the manufacturer’s instructions. q-rtPCR was performed using SYBR green master mix (Qiagen) 
and Quantitect primers (Qiagen) (See Supplemental Table for complete primer list).  Data were analysed using 
the LightCycler system and normalized to the housekeeping gene Gapdh. All samples were run in triplicate. 
 
Elisa detection of IGF1 Conditioned medium from BMOL cells for 48 hours was tested for IGF1 concentration 
using an IGF1 Mouse ELISA kit (Abcam ab100695) following the manufacturer’s protocol. A standard curve was 
generated using protein standards within the kit and absorbance of this and test samples were read using a 
spectophotometer (SPECTROstar Omega). This was normalised to protein content of secreting cells (determined 
using a BSA standard and Pierce reagent) as a surrogate for cell number. 
 
Serum analysis: Serum analysis used commercial kits according to the manufacturer’s instructions; serum 
albumin (Alb), bilirubin and alanine transaminase (ALT) (Alpha Laboratories); aspartate aminotransferase (AST) 
and alkaline phosphatase(ALP) (Randox laboratories); Cholesterol (Wako Chemicals GmbH). All kits were 
adapted for use on a Cobas Fara centrifugal analyser (Roche Diagnostics). 
 
Immunoblotting: Cells extracts were prepared from BMOL cells treated with DAPT (10μM) or vehicle for 48 
hours.  Protein content was quantified using a BSA standard and Pierce reagent before being resolved using SDS-
PAGE. Immunoblots were incubated at 4°C overnight with primary antibody rabbit anti-Igf1RY1161 (Abcam) or 
anti-beta-actin clone AC-74 (Sigma-Aldrich). Appropriate horseradish peroxidase labelled secondary antibodies 
were used (Cell Signaling Technologies) and signal detected with ECL reagent (Thermo Scientific).   
 
Statistical analysis: Prism software (GraphPad Software version 8) was used for all statistical analysis. Data are 
presented as mean ± s.e.m. n refers to biological replicates. Normal distribution of data was determined using 
the D’Agostino and Pearson omnibus normality test. For parametric data, data significance was analysed using 
a two-tailed unpaired Student’s t-test. In cases where more than two groups were being compared, then a one-
way ANOVA was used. In instances where the n was too small to determine normal distribution or the data were 
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non-parametric then a two-tailed Mann–Whitney U-test was used. Kruskall-Wallis test was used when 
comparing multiple non-parametric data.  
 
Normal distribution was determined by Shapiro-Wilk test. The data was normally distributed and statistical 
significance was determined using unpaired t-test. Statistical significance was assumed at p < 0.05. Data is 
presented as mean ± standard error of the mean (SEM). 
 
Study approval: All studies involving human tissue were approved by the University of Edinburgh and NHS 
Lothian Academic and Clinical Central Office for Research Development (ACCORD) tissue governance unit.  
Supplementary Material: 
Supplementary Figure 1: Deletion of Mdm2 in hepatocytes induced apoptosis and induces BECs to proliferate  
Supplementary Figure 2: In vitro inhibition of Notch signalling reduces BEC proliferation.  
Supplementary Figure 3: Supplementary Figure 3: Notch signalling regulates IGF1 sensitivity by regulating IGF1R 
activity  
Supplementary Figure 4: mTOR signalling can control BEC proliferation following hepatic injury. 
Supplementary Figure 5: Single channel images of immunohistochemical staining in this manuscript. 
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Figure 1: Notch pathway activation precedes BEC proliferation. A. Quantification of panCK positive BECs between 
day 0 (initiation of injury) and d14 following injury and the proportion of panCK positive BECs that are 
proliferating, immunostained with Ki67.  B. Immunohistochemistry of panCK positive bile ducts and BECs (green) 
and Ki67 (red) following initiation of injury. Yellow arrows denote nuclear positivity of Ki67 and white denotes 
DNA. C. mRNA expression of Notch1 and Notch3 in whole liver tissue following injury induction. D. Notch ligands, 
Jagged-1 and Jagged-2 mRNA expression over the injury time course. E. Immunostaining of Ah-
Cre::Mdm2fl/fl::CBFH2Bvenus mice five days following induction. (Keratin-19, green, Venus (reporting Notch 
activity), magenta). Yellow box denotes zoomed in region in lower panel. F. Immunofluorescent staining of 
NOTCH1 (3 days following injury) and NOTCH3 (five days following injury), pink, and Keratin-19 (demarcating 
BECs), left hand panels. G. Immunofluorescent staining of the Notch-ligand, JAGGED-1 (green) and either F4-80, 
αSMA or Keratin-19 (magenta), all five days post-injury. Yellow arrows denote Jagged-1 negative cells. White 
arrows denote Jagged-1 positive cholangiocytes. In all immunofluorescent staining, DNA is stained white. Scale 
Bar = 50μm. p.v. denotes portal vein.  N=6 per group. Each point represents a biological replicate. Data was 








Figure 2: Inhibition of specific Notch receptors alters BEC proliferation and differentiation in vivo. A. Schematic 
representation of early and late inhibition of Notch signalling during hepatocyte regeneration from BECs in the 
Mdm2 model. B. Quantification of proliferative (Ki67 positive) BECs (red dots) and total number of panCK 
positive BECs (blue dots) following Notch inhibition with DAPT either early in regeneration (left panel) or late in 
regeneration (right panel).  C. Immunohistochemistry for BECs (stained with panCK) following inhibition of Notch 
signalling with DAPT either early or late following injury. D. Quantification of the number of proliferating (Ki67 
positive) BECs (red dots) and total number of panCK positive BECs (blue dots) following inhibition with a blocking 
antibody targeting Desmin (an intermediate filament protein that serves as a control) and receptor specific 
blocking antibodies targeting either NOTCH1 or NOTCH2 (left panel). Individual groups represent distinct 
antibody clones. Right panel, proportion of proliferating (Ki67 positive) BECs (red dots) and total number of 
panCK positive BECs (blue dots) following Mdm2-loss induced injury in mice with either wild-type 
(Notch3WT/WT)or null for Notch3 (Notch3-/-). E. Schematic representation of lineage tracing BECs into hepatocytes 
using OPN-iCreERT2::R26ReYFP transgenic mice treated with a Choline Deficient, Ethionine Supplemented (CDE) 
diet. F. Immunohistochemistry showing eYFP positive cells during hepatic repair in control and Notch-i treated 
mice. G. Quantification of the number of eYFP (lineage-traced) hepatocytes following Notch-i treatment. Scale 
Bar = 50μm. p.v. denotes portal vein.  N≥4 per group. Each point represents a biological replicate. For data with 
two groups, a Student’s t-test was performed where multiple groups are analysed an ANOVA and a Dunnett’s 









Figure 3: Notch signalling regulates IGFR1 expression in BECs, to regulate their proliferation. A. 
Immunofluorescent staining of IGF1 (pink) in BECs (stained with Keratin-19, green), left panel and 
phosphorylated IGF1RY1161 (pink) in BECs (green), right panel at day 7 following injury. DNA is in white. Yellow 
arrows denote co-positivity. Inset images represent area of interest at an increased magnification. B. ELISA for 
IGF-1 secreted into the media by the BMOL BEC cell lines. C. mRNA expression of Igfr1 in BECs treated with 
vehicle or Notch-i, DAPT in vitro. D. Protein levels of total IGF1R normalised to β-actin levels following Notch-i 
treatment. E. mRNA expression of IGF1 and IGF1R in liver tissue undergoing hepatocyte regeneration treated 
with vehicle or Notch-i, DAPT. F. Immunohistochemical staining for phosphorylated IGF1RY1161 in animals 
undergoing hepatocyte regeneration treated with either vehicle or Notch-i. Black arrows denote membrane 
staining. G. Schematic detailing the strategy to delete Igf1r in BECs using the OPN-iCreERT combined with an 
Igf1flox allele treated and with CDE to induce hepatocyte injury, regeneration and BEC proliferation. H. Proportion 
of eYFP positive BECs that are proliferative, determined through co-positivity with PCNA (left dot plot) and total 
number of BECs following loss of IGF1R (right dot plot). Immunohistochemistry panels show representative eYFP 
staining (brown) of BECs in IGF1RWT and IGF1Rflox mice at week five. Scale Bar = 50μm. p.v. denotes portal vein.  
N=6 per group. Each point represents a biological replicate. For data with two experimental groups, a Student’s 








Figure 4: Therapeutic IGF1R modulation regulates BEC number in vivo but does not promote reconstitution of 
the parenchyma. A. Proportion of Ki67 (proliferative) BECs (left dot plot) and total number of BECs (right dot 
plot) in vehicle treated or IGF1R-inhibitor (AG1024) treated mice, and B immunohistochemistry showing panCK-
positive BECs following hepatocyte Mdm2-loss and treatment with IGF1R-inhibitor or vehicle alone. C. 
Proportion of Ki67 (proliferative) BECs (left dot plot) and total number of BECs (right dot plot) in vehicle treated 
or rIGF1 treated mice, and D. immunohistochemistry showing panCK-positive BECs following hepatocyte Mdm2-
loss and treatment with rIGF1 or vehicle alone. E. Schematic detailing the approach taken to determine whether 
rIGF1-induced BEC expansion results in the formation of more parenchymal hepatocytes. F. Proportion of PCNA-
positive (proliferative) BECs (left dot plot) and total number of BECs (right dot plot) in vehicle treated or rIGF1 
treated mice following injury. G. Proportion of HNF4α positive hepatocytes that are also positive for tdTomato 
(lineage traced) in vehicle and rIGF1 treated animals having received hepatocyte injury with MCD and H. 
Immunofluorescence of tdTomato (yellow) and HNF4α (magenta) at day 52 following MCD injury and rIGF1 
treatment. Blue arrows denote tdTomato positive BECs and white arrows denote tdTomato positive, lineage 
traced hepatocytes. Lower panels demonstrate tdTomato positive hepatocytes detected with DAB (black 
arrows), red arrows denote tdtomato positive BECs. I. Diagram showing our model, in which Notch signalling 
promotes BEC proliferation by rIGF1, yet differentiation into hepatocytes is not increased. Scale Bar = 50μm. p.v. 
denotes portal vein.  N≥3 per group. Each point represents a biological replicate. For data with two experimental 













Supplementary Figure 1: Deletion of Mdm2 in hepatocytes induced apoptosis and induces BECs to proliferate. 
A. Blood serum biochemistry for liver function at baseline (d0) and d3 and d7 following Mdm2 inactivation. B. 
Immunohistochemistry showing positivity for cleaved Caspase-3 (red) following inactivation of Mdm2 in 
hepatocytes. DNA is shown in white. Yellow box denotes region of high magnification image, inset. White arrows 
denote Caspase-3 positive hepatocytes.  C. Immunohistochemical staining of BECs using the markers Keratin-19 
(upper panels) and SOX9 (lower panels) following hepatocyte loss of Mdm2. D. mRNA expression following the 
recombination of Mdm2 in hepatocytes, for Notch2 and Dll1, a Notch receptor ligand. mRNA expression is 
normalised to the housekeeping gene Gapdh. Notch4 and Dll3 and Dll4 were not detectable by qRT-PCR. Scale 
bar = 50μm. N=4-6 per group. Each point represents a biological replicate. For data with two groups, a Student’s 









Supplementary Figure 2: In vitro inhibition of Notch signalling reduces BEC proliferation. A. MTT assay showing 
the response of BECs in vitro when treated with a scaling dose of Notch-i, DAPT or vehicle alone. B. The number 
of Edu-positive (proliferating) BECs in vitro when treated with the Notch-i, DAPT or vehicle alone. C. mRNA 
expression of Notch pathway target genes Hey1 and Hes1 following Notch pathway inhibition. D. MTT assay of 
BECs following treatment with a control blocking antibody targeting the intermediate filament protein, Desmin 
or targeting either NOTCH1 or NOTCH2 specifically. Individual groups represent distinct antibody clones. E. 
mRNA expression of Notch3 in BECs in vitro following treatment with two RNAi targeting Notch3 normalised to 
cells treated with a scrambled RNAi. F. Number of Ki67 positive BECs in vitro following knock-down of Notch3 
compared to untransfected and scrambled RNAi transfected cells. G. Blood serum biochemistry for ALT following 
Mdm2 inactivation and early (days 2-4) treatment with the Notch-i, DAPT H. Blood serum biochemistry for ALT 
following Mdm2 inactivation and late (days 7-9) treatment with the Notch-i, DAPT. I. Blood serum biochemistry 
for ALT following Mdm2 inactivation and treatment with either NOTCH-1, NOTCH-2 or Desmin (an intermediate 
filament protein that acts as a control) blocking antibodies. J. Blood serum biochemistry for ALT following Mdm2 
inactivation in mice harboring wild-type Notch3 or null for Notch3 (Notch3-/-).  K. Blood serum biochemistry for 
Bilirubin following Mdm2 inactivation and treatment with either NOTCH-1, NOTCH-2 or Desmin (an intermediate 
filament protein that acts as a control) blocking antibodies. L. Blood serum biochemistry for Bilirubin following 
Mdm2 inactivation in mice harboring wild-type Notch3 or null for Notch3 (Notch3-/-).  N=4-6 per group. Each 
point represents a biological or experimental replicate. For data with two groups, a Student’s t-test was 









Supplementary Figure 3: Notch signalling regulates IGF1 sensitivity by regulating IGF1R activity. A. Dot plots 
showing that the Notch-i, DAPT reduces proliferation of BECs in the Choline Deficient Ethionine-Supplemented 
(CDE), left graph, and Methionine-Choline Deficient, MCD diet, right graph. B. mRNA expression of Igf1 in pBECs 
following treatment with the Notch-i, DAPT. C. mRNA expression of Igf1R and the Notch target gene, HeyL in 
whole liver tissue following induction of hepatic injury. D. Protein expression of IGF1R in vehicle treated pHPCs, 
compared to pHPCs treated with Notch-i, DAPT. N≥5 per group. Each point represents a biological replicate. For 
data with two groups, a Student’s t-test was performed where multiple groups are analysed an ANOVA and a 










Supplementary Figure 4: mTOR signalling can control BEC proliferation following hepatic injury. A. MTT assay of 
HPC growth with escalating concentrations of AG1024, an IGF1R-i or vehicle alone. B. Immunohistochemistry of 
phosphorylated mTOR in HPCs undergoing hepatocyte regeneration. C. Quantification of total Keratin-19 
positive BEC number, left graph, and Ki67 positive (proliferating) BECs, right graph, following induction of 
hepatocyte regeneration and subsequent treatment with the mTOR inhibitor, Rapamycin. D. 
Immunohistochemistry of panCK positive BECs in livers where Mdm2 has been inactivated and animals have 
been treated with either vehicle or Rapamycin, images represent animals that were culled at 10 days following 
initiation of injury and which were treated with Rapamycin or vehicle from days 6-9. N≥3 per group. Each point 
represents a biological replicate or experimental replicate. Scale bar = 50μm For data with two groups, a 








Supplementary Figure 5: Single channels of immunofluorescence presented within this study. A-C. Single 
fluorescent channels from Figure 1: Notch pathway activation precedes BEC proliferation. D Single fluorescent 
channels from Figure 3: Notch signalling regulates IGFR1 expression in BECs, to regulate their proliferation. 
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Supplementary Table 1: Antibodies and Primers used in this study. 
Antibodies used in this study 
Caspase-3 Cell Signalling 9662 
CK19 
Developmental studies hybridoma 
bank 
Troma-III 
Hnf4α R&D systems H1415 
IGF1 Abcam ab40657 
IGF1 receptor β Cell Signalling Technologies 9750 
Jagged-1 Abcam ab109536 
Ki67 Abcam ab16667 
mCherry Sicgen #AB0081 
Notch1-ICD Abcam Ab8925 
Notch3 Abcam Ab23426 
panCK DAKO Z0622 
PCNA Abcam ab29 
YFP Abcam ab6673 
Primers used in this study 
Dll1 Qiagen QT00113239 
Dll3 Qiagen QT00113477 
Dll4 Qiagen QT01053598 
Gapdh Qiagen QT01658692 
Hes1 Qiagen  QT00313537 
Hey1 Qiagen QT00115094 
Igf1 Qiagen QT00154469 
Igf1r Qiagen  QT00155351 
Jagged1 Qiagen  QT00115703 
Jagged2 Qiagen  QT01043819 
Notch1 Qiagen  QT00156982 
Notch2 Qiagen  QT00153496 
Notch3 Qiagen  QT01051729 
Notch4 Qiagen  QT00135653 
 
 
